Monoclonal antibodies to programmed death 1 (PD-1)
US11414487B2 · kind B2 · utility
0Cited by
4References
18Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 21, 2016 |
| Grant date | Aug 16, 2022 |
| Priority date | — |
| Expiry date | Jun 18, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides PD-1 monoclonal antibodies, particularly human monoclonal antibodies of PD-1, which specifically bind to PD-1 with high affinity and comprise a heavy chain and a light chain. The present invention further provides nucleic acid sequence encoding the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. Immunoconjugates, therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating various cancers with anti-PD-1 antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.